Skip to main content
Clinical Trials/NCT02961634
NCT02961634
Unknown
Phase 3

Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis

Overview

Phase
Phase 3
Intervention
Nailner 2 in 1
Conditions
Onychomycosis
Sponsor
MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA
Enrollment
46
Primary Endpoint
Percent of improvement of mycosis by reducing the area of the lesion that will be measured at times D1 and D90
Last Updated
9 years ago

Overview

Brief Summary

Single-center study, single blind, comparative with the objective of evaluating the efficacy and safety of an investigational product as an adjunct in the treatment of onychomycosis improvement of 90 days ± 2 days.

Registry
clinicaltrials.gov
Start Date
April 2017
End Date
August 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Volunteers of both sexes;
  • Volunteers aged 18-65 years;
  • Volunteers with onychomycosis confirmed by positive direct mycological nail of hands or feet;
  • Agreement to comply with the test procedures and attend the clinic in the days and times for certain applications and / or assessments;
  • Understand, consent and sign the Instrument of Consent of Clarified.

Exclusion Criteria

  • Pregnancy or risk pregnancy / lactation;
  • Use of anti-inflammatory / immunosuppressive drugs (in the last 30 days and during the study);
  • Concomitant nail pathologies (psoriasis, lichen planus, etc.);
  • Systemic conditions that may compromise the growth of the nail (vascular disease, diabetes, etc.);
  • Irritation History to similar products to the investigational product;
  • Treatment with antifungal medication prior to the study (up to 12 weeks for systemic medications and topical medications for four weeks);
  • Other conditions considered by the investigator physician as reasonable for the disqualification of the individual's participation in the study.

Arms & Interventions

Nailner 2 in 1 + Ciclopirox 8%

Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail. They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.

Intervention: Nailner 2 in 1

Nailner 2 in 1 + Ciclopirox 8%

Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail. They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.

Intervention: Ciclopirox 8%

Ciclopirox 8%

Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.

Intervention: Ciclopirox 8%

Outcomes

Primary Outcomes

Percent of improvement of mycosis by reducing the area of the lesion that will be measured at times D1 and D90

Time Frame: 90 days

The improvement rate will be by measuring the area of the nail affected in millimeters (millimeters). The measurement will be taken with a ruler in the direction of the width and length of the lesion (mm2)

Secondary Outcomes

  • Number of patients reporting reduction in discomfort caused by onychomycosis through a subjective evaluation questionnaire(45 and 90 days)
  • Presence of fungal structures in nail affected by onychomycosis in visits 1 and final through mycological examination(90 days)
  • Number of adverse events reported and related to the product investigational(90 days)

Similar Trials